

Proteus Digital Health

helius

Proteus Digital Health

250+ employees 10 Years R&D Unique sensors & algorithms Hardware & applications software Medical & wellness product development Commercial-scale manufacturing Entering commercialization phase



Redwood City, USA R&D











Proteus Corporate Summary

Investors	Board and Management	Commercial Partners	Technology
Private Equity and VC Carlyle Group Essex Woodlands Adams Street Partners Spring Ridge Ventures Fletcher Spaght YF Capital Corporate Novartis Otsuka Oracle Medtronic St Jude Kaiser ON Semiconductor Over \$200MM in equity Over \$350MM total capital	Frank Fischer Ventritex, Neuropace Robert Epstein Merck, Medco Alan Levy Medicines Company, Intuitive Myrtle Potter Genentech, BMS, Amazon Ryan Schwarz Carlyle Charlie Songhurst Microsft Immanuel Thangaraj Essex Woodlands Management Andrew Thompson, CEO IPO and M&A success Markus Christen, Development Global Head BD&L NVS Diagnostics Donald Cowling, Commercial \$1B+ in digital product sales Ben Costello Head of operations, Dicon Tony Levitan, People CEO eGreetings David O'Reilly, Product Personalized medicine leader George Savage, Medical 8 FDA approvals Mark Zdeblick, Technology 100+ patents	Otsuka NOVARTIS ORACLE STIFFE INHS England	All developed in-house 500+ active patent filings 130+ issued patents





Silicon: 0.9mg - Bananas have 5mg per 100 grams Copper: 0.02mg - Cashews have 2.2mg per 100 grams Magnesium: 0.01mg - Halibut has 107mg per 100 grams

THE WORLD'S FIRST INGESTIBLE SENSOR

Proteus ingestible sensor is the size of a pencil tip













Pathway to Digital Medicine: 24 Months and \$4.5 Million







Digital NDA

Ingestible Sensor approved as medical device

- Unlimited use by patients ingesting up to 30 sensors per day

Approval pathway agreed by agency leadership for adding sensor to existing drugs

- No additional safety or efficacy data required
- No bioequivalence data required for similar formulation
- Approval standard: manufacturing data package (e.g., stability)
- Opportunity to shorten timeline for future products

Pathway confirmed in meetings with agency review staff on specific digital medicines

Initial indications favorable for similar path in China and Japan

Conventional NDA

Phase I, II and III clinical trials focused on safety and efficacy data On average 132 months and \$4.5 Billion



Product Progression

	Today	2015	2015 onwards
Focus	Introduction to Service	Scaled Adoption	Digital Medicines
Ingestible	Co-Ingestion Digital Tablets (co-package optional)	On Demand Digital Medicines (coencapsulation)	Integrated Digital Medicines (co- manufacturing)
Wearable		KAISER PERMANENTE	Otsuka
Application		Same Same	CLUCOSE Training Converted, Milight Missed Sugar. Page 1 10 10 10 10 10 10 10 10 10 10 10 10 1



Proteus Product in Action Today – Supporting Clinical Practice

Uncontrolled Hypertension

 Simple clinical evaluation tool to distinguish between lack of therapeutic response to treatment and sub-optimal medication taking

Transition to Home

 Simple tool to sustain patients at home, act as an early warning of need


Diabetes

 Simple tool to sustain and maintain patients medication taking and activity targets. Also engage patients and informal carers

Dementia

 Simple tool to communicate medicine taking and activity habits to patients, families and healthcare professionals













helius —






helius —








Medication taken







Time spent sitting








Time spent moving





helius —





Importance of Adopting Innovation Early

Mobile Phone Evolution



Without early bricks – no smart phones today



Helius Tomorrow


Digital Medicines

Integrated into Clinical Practice



Bridging The Gap

Need real world use – in Practice Clinician and Patient feedback Demonstrate Viability Uncover Weakness Improve and Develop



CE Mark

Co-Ingestion

Improving usability

Demonstrating Value

